Tatiana Ort

Company: AstraZeneca

Job title: Head of Bioscience, Immunology

Seminars:

Engineering the Next Generation of T-Cell Engagers Through Selective Activation to Improve Specificity, Potency & Safety 10:00 am

Advancing beyond first-generation TCEs by unpacking the rationale behind engineering trispecific molecules to selectively engage CD8+ T-cells and how this improves specificity and reduces off-target activity in autoimmune disease Designing conditional activation for enhanced safety: Explore how activity restricted to target-bound TCEs helps minimize unwanted immune activation and cytokine release, with implications for autoimmune disease…Read more

day: Day Two

Panel Discussion: Investigating Preclinical Platforms for Autoimmune T-Cell Engagers From Human Relevant Assays to Regulatory Confidence 2:40 pm

For TCEs in autoimmunity, conventional preclinical tools, often adapted from oncology, fall short in capturing the inflammatory, chronic, and tissue-specific nature of disease. This panel will explore how to build assays that reflect real autoimmune biology, capture safety-relevant signals, and avoid reliance on transgenic animals. With human target expression and immune context being essential, developers…Read more

day: Day Two